|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61P 29/00 | (2006.01) | ||
| C07K 16/24 | (2006.01) |
| (11) | Number of the document | 2902039 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15156029.9 |
| Date of filing the European patent application | 2005-08-04 | |
| (97) | Date of publication of the European application | 2015-08-05 |
| (45) | Date of publication and mention of the grant of the patent | 2018-04-11 |
| (46) | Date of publication of the claims translation | 2018-06-25 |
| (30) | Number | Date | Country code |
| 0417487 | 2004-08-05 | GB |
| (72) |
Di Padova, Franco E, CH
Gram, Hermann, DE
Hofstetter, Hans, CH
Jeschke, Margit, CH
Rondeau, Jean-Michel, CH
Van Den Berg, Wim, NL
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antagonistiniai IL-17 antikūnai |
| IL-17 antagonistic antibodies |
| Payment date | Validity (years) | Amount | |
| 2024-07-18 | 347.00 EUR |